FrancophonIA/ELRC3.0 huggingface dataset:
English: During post-marketing use in this age group, cases of hallucinations (associated with anxiety manifestations) and sleep disorders correlated with oxybutynin have been reported.
Slovenian: V obdobju trženja so pri tej starostni skupini poročali o primerih halucinacij (povezanih s pojavom tesnobnosti) in motenj spanja, ki so bili v korelaciji z oksibutininom.
English: Kentera is not recommended for use in the paediatric population.
Slovenian: Uporaba zdravila Kentera pri pediatrični populaciji ni priporočljiva.
English: Children may be more sensitive to the effects of the product, particularly the CNS and psychiatric adverse reactions.
Slovenian: Otroci so morda občutljivejši za učinke tega zdravila, zlasti za neželene učinke na centralni živčni sistem in psihiatrične neželene učinke.
English: […] Tabulated list of adverse reactions
Slovenian: […] Preglednica z neželenimi učinki
English: Kentera should be used with caution in elderly patients, who may be more sensitive to the effects of centrally acting anticholinergics and exhibit differences in pharmacokinetics (see section 4.4).
Slovenian: Pri starejših bolnikih je treba zdravilo Kentera uporabljati previdno, ker so lahko občutljivejši za učinke antiholinergikov s centralnim delovanjem in lahko pri njih obstajajo razlike v farmakokinetiki (glejte poglavje 4.4).
English: - anxiety - confusion - nervousness - agitation - difficulty in sleeping
Slovenian: - tesnobnost - zmedenost - živčnost - vznemirjenost - težave s spanjem
English: Applicable to all formulations: Kentera 3.9 mg / 24 hours transdermal patch, Kentera 90.7 mg/g gel in sachet and Kentera 90.7 mg/g gel in a metering pump
Slovenian: Velja za vse formulacije: Kentera 3,9 mg/24 h transdermalni obliž, Kentera 90,7 mg/g gel v vrečici in Kentera 90,7 mg/g gel v odmerni črpalki
English: Memory impairment#, amnesia#, lethargy#, disturbance in attention#
Slovenian: motnje spomina#, amnezija#, letargija#, motnje pozornosti#
English: Caution should be exercised when oxybutynin is administrated concomitantly with other anticholinergic medicines (see also section 4.5).
Slovenian: Pri dajanju oksibutinina sočasno z drugimi antiholinergičnimi zdravili je potrebna previdnost (glejte tudi poglavje 4.5).
English: Other psychiatric events implying an anticholinergic mechanism have been reported during postmarketing use (see section 4.8).
Slovenian: Med obdobjem trženja so poročali tudi o drugih psihiatričnih učinkih, ki kažejo na antiholinergični mehanizem (glejte poglavje 4.8).
English: Applicable to Kentera 3.9 mg / 24 hours transdermal patch only
Slovenian: Velja samo za zdravilo Kentera 3,9 mg/24 h transdermalni obliž
English: Rare side effects: - panic reaction - mental confusion - hallucinations - disorientation - memory impairment - loss of memory - abnormal tiredness
Slovenian: Redki neželeni učinki: - panična reakcija - duševna zmedenost (delirij) - halucinacije - dezorientiranost
English: Psychiatric and CNS anticholinergic events like sleep disorders (e.g. insomnia) and cognitive disorders have been associated with oxybutynin use, especially in elderly patients.
Slovenian: Z uporabo oksibutinina, zlasti pri starejših bolnikih, so povezani antiholinergični učinki na duševno zdravje in centralni živčni sistem, kot so motnje spanja (npr. nespečnost) in kognitivne motnje.
English: Anxiety, confusion, nervousness, agitation, insomnia
Slovenian: Psihiatrične motnje tesnobnost, zmedenost, živčnost, vznemirjenost, nespečnost panična reakcija#, delirij#, halucinacije#, dezorientiranost#
English: 90.7 mg/g gel in sachet and Kentera 90.7 mg/g gel in a metering pump 4.2 Posology and method of administration […] Elderly population
Slovenian: Velja za vse formulacije: Kentera 3,9 mg/24 h transdermalni obliž, Kentera 90,7 mg/g gel v vrečici in Kentera 90,7 mg/g gel v odmerni črpalki 4.2.
English: Date of first authorisation: 26 April 2019
Slovenian: Datum prve odobritve: 26 April 2019
English: Open here
Slovenian: odprite tukaj
English: However, this observation is based on a limited number of subjects.
Slovenian: Vendar to opažanje temelji na omejenem številu preiskovancev.
English: How much?
Slovenian: Koliko?
English: • if you have tuberculosis (TB).
Slovenian: • če imate tuberkulozo (TB).
English: 67061 Ludwigshafen Germany
Slovenian: 67061 Ludwigshafen Nemčija
English: • Do not inject through clothes
Slovenian: • Ne injicirajte skozi oblačila.
English: Campoverde di Aprilia (LT) ITALY
Slovenian: Campoverde di Aprilia (LT) Italija
English: Weeks After Re-Randomisation
Slovenian: Tedni po ponovni randomizaciji
English: • It is normal to see bubbles in the window
Slovenian: • Normalno je, da v okencu vidite mehurčke.
English: This is normal
Slovenian: To je normalno.
English: • if the expiry date (EXP) has passed
Slovenian: • če je rok uporabnosti (EXP) že pretekel,
English: • Do not inject into areas affected by psoriasis
Slovenian: • Ne injicirajte v predele, ki jih je prizadela psoriaza.
English: Thereafter, dosing should be resumed at the regular scheduled time.
Slovenian: Potem je treba uporabo zdravila nadaljevati ob redno predvidenem času.
English: If you stop treatment, your symptoms may come back.
Slovenian: Če zdravilo prenehate uporabljati, se vam simptomi lahko ponovijo.
English: All comparisons achieved p<0.001
Slovenian: Vse primerjave so dosegle p < 0,001
English: • if the liquid has ever been frozen (even if thawed)
Slovenian: • če je bila tekočina kdaj zmrznjena (tudi če se je odtalila),
English: Slowly take your thumb off the plunger.
Slovenian: Počasi odmaknite palec z bata.
English: Elderly (aged 65 years and over)
Slovenian: Starejši bolniki (stari 65 let ali več)
English: Human IgGs are known to be excreted in breast milk during the first few days after birth, which decreases to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period.
Slovenian: Znano je, da se človeški IgG izločajo v materino mleko prvih nekaj dni po rojstvu, a se njihova koncentracija kmalu potem zelo zmanjša; tveganja za dojenega otroka med tem kratkim obdobjem tako ni mogoče izključiti.
English: Hold the body of the syringe in one hand between the thumb and index finger, like you would a pencil.
Slovenian: Držite telo brizge z eno roko med palcem in kazalcem, kot bi držali svinčnik.
English: The same information is also available at the following URL: www.skyrizi.eu
Slovenian: Iste informacije so na voljo tudi na naslednjem URL: www.skyrizi.eu
English: The most frequently reported adverse reactions were upper respiratory infections, which occurred in 13% of patients.
Slovenian: Najpogosteje opisani neželeni učinki so bile okužbe zgornjih dihal, ki so se pojavile pri 13 % bolnikov.
English: DLQI 0 or 1
Slovenian: DLQI 0 ali 1
English: sPGA of clear or almost clear (0 or 1)
Slovenian: Ocena sPGA čisto ali skoraj čisto (0 ali 1)
English: • You may see a drop of liquid at the end of the needle.
Slovenian: • Na koncu igle se lahko pojavi kapljica tekočine.
English: Store in a refrigerator (2°C - 8°C).
Slovenian: Shranjujte v hladilniku (2 - 8 °C).
English: Week 16
Slovenian: 16. teden
English: • swelling of the face, lips, tongue or throat
Slovenian: • oteklost obraza, ustnic, jezika ali žrela,
English: If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab.
Slovenian: Če je bolnik prejel živo cepivo (virusno ali bakterijsko), je priporočljivo počakati vsaj 4 tedne pred začetkom zdravljenja z risankizumabom.
English: The safety and efficacy of Skyrizi in children and adolescents aged 6 to 18 years have not yet been established.
Slovenian: Varnost in učinkovitost zdravila Skyrizi pri otrocih in mladostnikih od 6. do 18. leta starosti še nista ugotovljeni.
English: Do not inject into the same place.
Slovenian: Ne injicirajte obeh na isto mesto.
English: RZB = risankizumab UST = ustekinumab PBO = placebo p<0.001 at each time point
Slovenian: RZB = risankizumab UST = ustekinumab PBO = placebo p < 0,001 na vseh časovnih točkah
English: Gender or race
Slovenian: Spol ali rasa
English: No dose adjustment is required (see section 5.2).
Slovenian: Odmerka ni potrebno prilagoditi (glejte poglavje 5.2).
English: • if you are using, have recently used or might use any other medicines.
Slovenian: • če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
English: Start with one syringe for the first injection.
Slovenian: Začnite z eno injekcijsko brizgo za prvo injekcijo.
English: • Repeat Steps 2 through 6 with the second syringe
Slovenian: • Ponovite korake od 2. do 6. še z drugo brizgo.
English: • if you have an infection, including active tuberculosis, which your doctor thinks is important.
Slovenian: • če imate kakšno okužbo (vključno z aktivno tuberkulozo), ki je po zdravnikovi presoji pomembna.
English: • if you currently have an infection or if you have an infection that keeps coming back.
Slovenian: • če imate trenutno kakšno okužbo, ali če imate kakšno okužbo, ki se ponavlja.
English: This is because it is not known how this medicine will affect the baby.
Slovenian: Ni namreč znano, kakšen vpliv ima to zdravilo lahko na otroka.
English: • Skyrizi should not be warmed in any other way (for example, in a microwave or in hot water)
Slovenian: • Zdravila Skyrizi ne segrevajte na noben drug način (na primer v mikrovalovni pečici ali v vroči vodi).
English: To listen to or request a copy of this leaflet in <Braille>, <large print> or <audio>, please contact the local representative of the Marketing Authorisation Holder.
Slovenian: Če želite poslušati ali zaprositi za kopijo tega navodila v <Braillovi pisavi>, <velikem tisku> ali <zvočnem posnetku>, se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
English: Very common: may affect more than 1 in 10 people • upper respiratory infections with symptoms such as sore throat and stuffy nose
Slovenian: Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 oseb • okužba zgornjih dihal s simptomi, kot so vneto grlo in zamašen nos
English: Your doctor will decide if you can keep using Skyrizi.
Slovenian: Zdravnik bo presodil, ali lahko še naprej uporabljate zdravilo Skyrizi.
English: Results are presented in Table 4.
Slovenian: Rezultati so prikazani v preglednici 4.
English: Table 1: List of adverse reactions in clinical studies
Slovenian: Preglednica 1: Seznam neželenih učinkov v kliničnih študijah
English: It reduces the inflammation.
Slovenian: Tako zmanjša vnetje.
English: • Special disposal container (not included in the carton)
Slovenian: • poseben vsebnik za odlaganje (ni priložen v škatli)
English: For more information and support on Skyrizi go to www.skyrizi.eu or scan this code.
Slovenian: Za več informacij in za podporo o zdravilu Skyrizi obiščite www.skyrizi.eu ali skenirajte to kodo.
English: Concomitant immunosuppressive therapy or phototherapy
Slovenian: Sočasno imunosupresivno zdravljenje ali fototerapija
English: • injection site reactions (such as redness or pain)
Slovenian: • reakcije na mestu injiciranja (kot sta rdečina ali bolečina)
English: Insert the needle all the way into the skin at about a 45-degree angle using a quick, short movement.
Slovenian: Iglo v celoti zabodite v kožo pod kotom približno 45 stopinj s hitrim, kratkim gibom.
English: As with all therapeutic proteins, there is the potential for immunogenicity with risankizumab.
Slovenian: Tako kot pri vseh terapevtskih beljakovinah tudi pri risankizumabu obstaja možnost imunogenosti.
English: Risankizumab clearance and volume of distribution increase as body weight increases which may result in reduced efficacy in subjects with high body weight (>130 kg).
Slovenian: Očistek in volumen porazdelitve risankizumaba se povečujeta s povečevanjem telesne mase, kar ima lahko za posledico zmanjšano učinkovitost pri osebah z visoko telesno maso (>130 kg).
English: If you forget to use Skyrizi, inject a dose as soon as you remember.
Slovenian: Če ste pozabili uporabiti zdravilo Skyrizi, injicirajte odmerek takoj, ko se spomnite.
English: Pull the needle out of the skin while keeping the syringe at the same angle.
Slovenian: Izvlecite iglo iz kože, medtem ko brizgo držite pod istim kotom.
English: A total of 9.8% of study subjects had a history of diagnosed psoriatic arthritis.
Slovenian: Skupno je imelo 9,8 % preiskovancev v študiji anamnezo diagnosticiranega psoriatičnega artritisa.
English: The safety and efficacy of risankizumab in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated.
Slovenian: Varnosti in učinkovitosti risankizumaba v kombinaciji z imunosupresivi, vključno z biološkimi zdravili, ali fototerapijo niso ocenili.
English: The safety profile of risankizumab with up to 77 weeks of exposure was consistent with the profile observed up to 16 weeks.
Slovenian: Varnostni profil risankizumaba pri izpostavljenosti do 77 tednov je bil skladen s profilom, opaženim pri izpostavljenosti do 16 tednov.
English: Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines.
Slovenian: Pred uvedbo zdravljenja z risankizumabom je treba razmisliti o dokončanju vseh ustreznih imunizacij v skladu s trenutnimi imunizacijskimi smernicami.
English: Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks.
Slovenian: Nekaterim bolnikom, ki se na začetku zdravljenja odzovejo le delno, se lahko stanje pozneje izboljša z nadaljevanjem zdravljenja več kot 16 tednov.
English: Removing the needle cover:
Slovenian: Odstranite pokrovček igle:
English: • Your doctor, pharmacist or nurse will tell you how to return the full special disposal container
Slovenian: • Zdravnik, farmacevt ali medicinska sestra vam bodo povedali, kako vrniti polni vsebnik za odlaganje.
English: • feeling tired or short of breath, cough which will not go away
Slovenian: • občutek utrujenosti, težko dihanje ali kašelj, ki ne izgine,
English: Maintenance of response
Slovenian: Vzdrževanje odziva
English: Comprehensive instructions for use are provided in the package leaflet.
Slovenian: Izčrpna navodila za uporabo so vključena v navodilu za uporabo.
English: You and your doctor, pharmacist or nurse will decide if you should inject this medicine yourself.
Slovenian: Skupaj z zdravnikom, farmacevtom ali medicinsko sestro se boste odločili, ali naj si zdravilo injicirate sami.
English: For most subjects, antibodies to risankizumab including neutralising antibodies were not associated with changes in clinical response or safety.
Slovenian: Pri večini preiskovancev protitelesa proti risankizumabu, vključno z nevtralizirajočimi protitelesi, niso bila povezana s spremembami kliničnega odziva ali varnosti.
English: • if you are allergic to risankizumab or any of the other ingredients of this medicine (listed in section 6).
Slovenian: • če ste alergični na risankizumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: The needle will then be covered by the needle guard.
Slovenian: Ščitnik igle bo nato pokril iglo.
English: The rate of serious infections was 1.7 events per 100 subject-years (see section 4.4).
Slovenian: Delež resnih okužb je bil 1,7 na 100 let izpostavljenosti preiskovancev (glejte poglavje 4.4).
English: Each pre-filled syringe is for single use only.
Slovenian: Vsaka napolnjena injekcijska brizga je le za enkratno uporabo.
English: Figure 2: Time course of PASI 90 after re-randomisation in IMMVENT
Slovenian: Slika 2: Časovni potek PASI 90 po ponovni randomizaciji v študiji IMMVENT
English: The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
Slovenian: Odkritje nastajanja protiteles proti zdravilu je močno odvisno od senzitivnosti in specifičnosti preizkusa.
English: Results 28 weeks after re-randomisation are presented in Table 5 and Figure 2.
Slovenian: Rezultati 28 tednov po ponovni randomizaciji so prikazani v preglednici 5 in na sliki 2.
English: Gently pinch the area of cleaned skin with your other hand and hold it firmly.
Slovenian: Nežno stisnite očiščeni predel kože z drugo roko in ga trdno držite.
English: Return this medicine to the pharmacy
Slovenian: Zdravilo vrnite v lekarno:
English: 20 and water for injections.
Slovenian: polisorbat 20 in voda za injekcije.
English: Skyrizi is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
Slovenian: Zdravilo Skyrizi je namenjeno za uporabo pod vodstvom in nadzorom zdravnika, ki ima izkušnje z diagnosticiranjem in zdravljenjem psoriaze.
English: Do not use this medicine after the expiry date which is stated on the syringe label and outer carton after ‘EXP'.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki injekcijske brizge in na zunanji ovojnini poleg oznake "EXP".
English: Check the liquid in the syringe.
Slovenian: Preverite tekočino v injekcijski brizgi.
English: Hold the syringe with the covered needle pointing down, as shown.
Slovenian: Primite injekcijsko brizgo s pokrito iglo obrnjeno navzdol, kot je prikazano.
English: In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution.
Slovenian: Pri bolnikih s kronično okužbo, anamnezo ponavljajoče se okužbe ali z znanimi dejavniki tveganja za okužbo, je treba risankizumab uporabljati previdno.
English: A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.
Slovenian: Potrebno je sprejeti odločitev glede prenehanja/prekinitve zdravljenja z risankizumabom, pri tem pa upoštevati koristi dojenja za otroka in koristi zdravljenja z risankizumabom za žensko.
English: There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of risankizumab in pregnant women.
Slovenian: Podatkov o uporabi risankizumaba pri nosečnicah ni ali jih je malo (manj kot 300 izidov nosečnosti).
English: Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection.
Slovenian: Pred uvedbo zdravljenja z risankizumabom je potrebno bolnike pregledati za okužbo s tuberkulozo (TB).
English: Talk to your doctor or get medical help immediately if you have symptoms of a serious infection such as:
Slovenian: Nemudoma se posvetujte z zdravnikom ali poiščite zdravniško pomoč, če se vam pojavijo simptomi resne okužbe, na primer:
English: 2 Injections Required
Slovenian: Potrebni sta 2 injekciji
English: IL-23 is a cytokine that is involved in inflammatory and immune responses.
Slovenian: IL-23 je citokin, ki sodeluje pri vnetnih in imunskih odzivih.
English: The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.
Slovenian: Upoštevati je treba aditivni učinek sočasnega jemanja zdravil, ki vsebujejo sorbitol (ali fruktozo), in sorbitola (ali fruktoze), ki ga vnesemo s hrano.
English: • warm, red and painful skin, or a painful skin rash with blisters
Slovenian: • topla, rdeča in boleča koža ali boleč kožni izpuščaj z mehurji.
English: • The needle guard will not activate unless all the liquid is injected
Slovenian: • Ščitnik igle se ne aktivira, dokler ni injicirana vsa tekočina.
English: The incidence of injection site reactions is numerically higher in the anti-drug antibodypositive compared with anti-drug antibody-negative groups over short-term (16 weeks: 2.7% vs 1.3%) and longer term treatment (>52 weeks: 5.0% vs 3.3%).
Slovenian: Incidenca reakcij na mestu injiciranja je številčno večja pri skupini, ki je pozitivna na protitelesa proti zdravilu v primerjavi s skupino, ki je negativna na protitelesa proti zdravilu, pri kratkoročnem (16 tednov: 2,7 % proti 1,3 %) in dolgoročnem zdravljenju (> 52 tednov: 5,0 % proti 3,3 %).
English: What Skyrizi is and what it is used for 2.
Slovenian: Kaj je zdravilo Skyrizi in za kaj ga uporabljamo 2.
English: As a precautionary measure, it is preferable to avoid the use of risankizumab during pregnancy.
Slovenian: Iz previdnosti se je uporabi risankizumaba med nosečnostjo bolje izogniti.
English: Patients should be instructed to inject 2 pre-filled syringes for the full 150 mg dose and to read the ‘Instructions for use' provided in the package leaflet before administration.
Slovenian: Bolnikom je treba naročiti, da si morajo za celoten 150-mg odmerek injicirati 2 napolnjeni injekcijski brizgi ter da morajo pred uporabo zdravila prebrati "Navodila za uporabo" v navodilu, priloženem zdravilu.
English: Over the entire psoriasis programme including long-term exposure to risankizumab, the rate of infections was 75.5 events per 100 subject-years.
Slovenian: V celotnem programu psoriaze, vključno z dolgoročno izpostavljenostjo risankizumabu, je bil delež okužb 75,5 na 100 let izpostavljenosti preiskovancev.
English: Uncommon: may affect up to 1 in 100 people • small raised red bumps on the skin
Slovenian: Občasni: pojavijo se lahko pri največ 1 od 100 oseb • majhne, dvignjene bulice na koži
English: Do not stop using Skyrizi without talking to your doctor first.
Slovenian: Ne prenehajte uporabljati zdravila Skyrizi, ne da bi se prej posvetovali z zdravnikom.
English: These conditions are generally not expected to have any significant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary (see section 5.2).
Slovenian: Na splošno ni pričakovati, da bi ta stanja pomembno vplivala na farmakokinetiko monoklonskih protiteles, zato prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
English: Slowly push the plunger all the way in until all of the liquid is injected.
Slovenian: Počasi potisnite bat do konca, dokler ne injicirate vse tekočine.
English: AbbVie (as logo)
Slovenian: AbbVie (kot logo)
English: Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC18
Slovenian: Farmakoterapevtska skupina: Zdravila za zaviranje imunske odzivnosti, zaviralci interlevkinov Oznaka ATC: L04AC18
English: • fever, flu-like symptoms, night sweats
Slovenian: • zvišana telesna temperatura, gripi podobni simptomi, nočno znojenje,
English: • PASI 90 continued to receive adalimumab
Slovenian: • PASI 90 so še naprej prejemali adalimumab.
English: This medicine is given as 2 injections under your skin (called ‘subcutaneous injections').
Slovenian: Zdravilo Skyrizi se uporablja v 2 podkožnih injekcijah (to imenujemo "subkutano injiciranje").
English: Following subcutaneous dosing of risankizumab, peak plasma concentrations were achieved between 3-14 days after dosing with an estimated absolute bioavailability of 89%.
Slovenian: Po subkutani uporabi risankizumaba je bila največja koncentracija v plazmi dosežena od 3 do 14 dni po uporabi ter z ocenjeno absolutno biološko uporabnostjo 89 %.
English: Of the 2,234 subjects with plaque psoriasis exposed to risankizumab, 243 were 65 years or older and 24 subjects were 75 years or older.
Slovenian: Od 2234 preiskovancev s psoriazo v plakih, izpostavljenih risankizumabu, je bilo 243 starih 65 let ali več in 24 starih 75 let ali več.
English: This medicine works by stopping a protein in the body called ‘IL-23', which causes inflammation.
Slovenian: To zdravilo deluje tako, da blokira telesno beljakovino "IL-23", ki povzroča vnetje.
English: Before injecting, patients may remove the carton from the refrigerator and allow to reach room temperature out of direct sunlight (15 to 30 minutes) without removing the pre-filled syringes from the carton.
Slovenian: Pred injiciranjem lahko bolniki vzamejo škatlo iz hladilnika in pustijo, da doseže sobno temperaturo (pri tem ne sme biti izpostavljena neposredni sončni svetlobi), tj. od 15 do 30 minut, ne da bi napolnjeno injekcijsko brizgo vzeli iz škatle.